Log In
BCIQ
Print this Print this
 

PUL-042

  Manage Alerts
Collapse Summary General Information
Company Pulmotect Inc.
DescriptionCombination of toll-like receptors agonists Pam2 and oligodeoxynucleotide
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationRespiratory infection
Indication DetailsTreat respiratory infections in cancer patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today